{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-040296","form_type":"8-K","ticker":"NNVC","cik":"0001379006","company_name":"NANOVIRICIDES, INC.","filed_at":"2023-03-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.691012+00:00","generated_at":"2026-06-17T07:41:20.407772+00:00","sec_items":["1.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"NanoViricides licenses COVID-19 drug candidates NV-CoV-2 and NV-CoV-2-R to Karveer for India","bullets":["Exclusive license for development and commercialization in India; Karveer to sponsor Phase I and II clinical trials.","NanoViricides reimburses all direct/indirect trial costs plus a 30% fee; Karveer pays 70% of invoiced commercial sales to NanoViricides.","No minimum royalties or license maintenance fees; term continues as long as Karveer uses NanoViricides' proprietary technologies.","NanoViricides retains full rights to clinical data for use outside India."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-040296","json":"https://secwatch.observer/filing/0001104659-23-040296.json","markdown":"https://secwatch.observer/filing/0001104659-23-040296.md","text":"https://secwatch.observer/filing/0001104659-23-040296.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1379006/000110465923040296/0001104659-23-040296-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1379006/000110465923040296/tm2311179d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T07:41:20.407772+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"fa2ef3d68ac600f23639aabc1c939deb448d8634","claim":"NANOVIRICIDES, INC. entered into License Agreement with Karveer Meditech Private Limited (effective 2023-03-27).","evidence_excerpt":"On March 27, 2023, NanoViricides, Inc. (the “Company”) entered into a License Agreement (the “Agreement”) with Karveer Meditech Private Limited (“Karveer”)","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1379006/000110465923040296/0001104659-23-040296-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"license"},{"label":"Counterparty","value":"Karveer Meditech Private Limited"},{"label":"Effective","value":"2023-03-27"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}